secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVAI BIO, INC. (AVAI)
CIK:        0001740797
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001740797-25-000020
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avant Technologies expands joint venture territory to global license; extends conditions deadline to Nov 2025
--------------------------------------------------------------------------------

- Addendum expands Ainnova’s Technology Portfolio license to global territory (previously North America and Europe).
- Conditions satisfaction deadline under Joint Venture Agreement extended from May 8, 2025 to November 8, 2025.
- Parties agree to possible merger terms as per Term Sheet signed September 21, 2024.
- Ai-nova Acquisition Corp, LLC formed December 6, 2024; jointly represented by CEOs of Avant and Ainnova.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740797/000174079725000020/0001740797-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740797/000174079725000020/avai_8k.htm
  HTML page:      https://secwatch.observer/filing/0001740797-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer